35 results on '"Granger, Chris"'
Search Results
2. Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
3. Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
4. ST Resolution 1 Hour After Fibrinolysis for Prediction of Myocardial Infarct Size: Insights from ASSENT 3
5. Differences in the Treatment of Myocardial Infarction between the United States and Canada: A Survey of Physicians in the GUSTO Trial
6. Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis
7. Effect of candesartan on New York Heart Association functional class: Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
8. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics
9. Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design
10. Does Vein Occupancy Matter?
11. CRT-200.92 Gender Disparities in ST-Elevation Myocardial Infarction Care and Outcomes in Emerging Countries: A Global Lumen Organization for Women (GLOW) Initiative and Call to Action
12. A Moment
13. Facilitated versus primary PCI for acute myocardial infarction
14. Differences in Treatment Patterns and Outcomes Between Hispanics and Non-Hispanic Whites Treated for ST-Segment Elevation Myocardial Infarction
15. Abstract 16674: Using Novel Emergency Medical Services Data-Linkage to Evaluate the Timing and Quality of Pre-Hospital ST-Elevation Myocardial Infarction Care
16. Abstract P93: Differences in Practice Patterns and Outcomes Between Hispanics and Non-Hispanic Whites Treated for ST-Segment Elevation Myocardial Infarction: Results From ACTION Registry - Get With the Guidelines
17. MORTALITY AND MORBIDITY REDUCTION BY PRIMARY PERCUTANEOUS CORONARY INTERVENTION IS CONSISTENT ACROSS SPECTRUM OF AGE
18. Time Course of Degradation of Cardiac Troponin I in Patients With Acute ST-Elevation Myocardial Infarction
19. Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
20. T Spot: A new test for tuberculosis infection
21. Thrombocytopenia Is More Common and Nadir Occurs Earlier with Unfractionated Heparin Than with Low Molecular Weight Heparin - Results from the Prospective Catch Registry.
22. Outcome after urgent percutaneous coronary interventions in ASSENT-3
23. Impact of enoxaparin and abcixlmab on bleeding complications in acute myocardial infarction: insights from assent-3
24. International differences in patients, care, and outcomes associated with acute myocardial infarction: the hero-2 trial
25. Treatment of Reinfarction After Thrombolytic Therapy for Acute Myocardial Infarction
26. Effect of candesartan on New York Heart Association functional class.
27. Les universités au risque de l’Histoire. Principes, configurations, modèles ed. by Yamina Bettahar and Marie-Jeanne Choffel-Mailfert (review)
28. Facilitated versus primary PCI for acute myocardial infarction – Authors' reply
29. Health Information Technology: Meaningful Use and Next Steps to Improving Electronic Facilitation of Medication Adherence
30. 1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study
31. 810-1 Impact of the angiotensin-receptor blocker candesartan in preventing diabetes in patients with heart failure
32. Differences in Treatment Patterns and Outcomes Between Hispanics and Non-Hispanic Whites Treated for ST-Segment Elevation Myocardial Infarction Results From the NCDR ACTION Registry–GWTG
33. TWISTED TRAILZ 1.
34. Abstract P93
35. Abstract P93
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.